BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) Receives Notice From IRS On Tax Allocation Dispute For 1997-2000


10/19/2005 5:12:33 PM

LONDON and PHILADELPHIA, Jan. 26 /PRNewswire-FirstCall/ -- As part of its long-running dispute with the US Internal Revenue Service (IRS), GlaxoSmithKline (GSK) announced today that, as expected, the company has now received a claim for additional taxes that the US government asserts legacy company, Glaxo Wellcome owes for the years 1997-2000. GSK disagrees with this tax claim, and the company believes that it has paid all the taxes owed to the U.S. Government for these years.

This Notice of Deficiency for $1.9 billion (1.0 billion pounds sterling) in tax, principally relates to the allocation of taxes on profits for Glaxo heritage products between the US and other countries. To the extent that the IRS is successful in this claim, interest would be payable. GSK estimates the interest to date would be approximately $700 million (380 million pounds), net of federal tax relief.

On January 7, 2004, GSK previously announced that the company had received a Notice of Deficiency for $2.7 billion in tax for the years 1989-1996, and estimated the interest charge for this claim would be approximately $2.5 billion net of federal tax relief. In making the announcement GSK said that it expected to receive a similar notice for the 1997-2000 period,

The company continues to believe, based on external professional advice, that it has made adequate provision for tax liabilities which could arise from these tax assessments. GSK also continues to believe that the profits reported by its US subsidiaries for the period 1989-2000, on which it has paid taxes in the United States, are more than sufficient to reflect the activities of its US operations.

There continues to be a wide difference of views between GSK and the IRS. GSK considers that the additional tax claim by the IRS on Glaxo heritage products is inconsistent with the treatment of other pharmaceutical companies, including GSK legacy company SmithKline Beecham. GSK plans to contest this claim for additional taxes.

Disagreements with and between revenue authorities as to tax allocations between related companies in different tax jurisdictions are inevitable for a global business such as GSK. The company attempted to resolve the dispute by referring it to negotiations between the US and UK tax authorities. The company believes these discussions collapsed when the UK supported the GSK position that no additional taxes were due to the IRS.

The Company will ask the US Tax Court to consolidate the 1997-2000 claim with the case currently pending before the court for the 1989-1996 tax years. A provisional date for the trial has been set for October 2006.

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, please visit the company's web site at http://gsk.com/.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2003.

GlaxoSmithKline

CONTACT: US Media inquiries: Nancy Pekarek, +1-215-751-7709, orMary Anne Rhyne, +1-919-483-2839, or Patty Seif, +1-215-751-7709; or UK Mediainquiries: Phil Thomson, 020 8047 5502, or Chris Hunter-Ward, 020 8047 5502,or David Mawdsley, 020 8047 5502; or US Analyst/Investor inquiries:Frank Murdolo, +1-215-751-7002, or Tom Curry, +1-215-751-5419; or EuropeanAnalyst/Investor inquiries: Duncan Learmouth, 020 8047 5540, orPhilip Thomson, 020 8047 5543, or Anita Kidgell, 020 8047 5542, all ofGlaxoSmithKline



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES